ArticleBMJ (Clinical research ed.)2024
25 year trends in cancer incidence and mortality among adults aged 35-69 years in the UK, 1993-2018: retrospective secondary analysis.
Article in BMJ (Clinical research ed.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 2 syntheses or guidelines pooled it, 75 citations in OpenAlex.
- Indications of Cannabinoids for the Palliation of Cancer-Associated Symptoms: A Systematic Review and Meta-Analysis.Current oncology reports · 2025Pooled it
- Comparing the diagnostic efficacy of [Frontiers in medicine · 2025Pooled it
- Supporting endocrine therapy adherence in women with breast cancer: findings from the ROSETA pilot fractional factorial randomized trial.Annals of behavioral medicine : a publication of the Society of Behavioral Medicine · 2025Trial
- Assessment of Factors and Trends Affecting Different Pathological Types of Cervical Cancer in China From 2013 to 2022.Cancer medicine · 2026Article
- Mental Health Conditions and Incident Cancer: A Prospective Cohort Study of 402,255 UK Biobank Participants.International journal of cancer · 2026Article
- Healthy lifestyle and cancer risk: a pan-cancer analysis in the UK Biobank prospective cohort.British journal of cancer · 2026Article
- Semantic CT features and differentiation model: new primary lung cancer versus metastasis after previous malignancy.European radiology · 2026Article
- The Burden and Risk Factors of Head and Neck Cancers in G20 Countries, 1990-2023.International dental journal · 2026Article
- A multi-centre real-world evaluation of AI-assisted organ at risk contouring on radiotherapy treatment planning workflows.The British journal of radiology · 2026Article
- Longevity-associatedTranslational lung cancer research · 2026Article
- Cancer trends in England in younger adults from 2001-2023: comparing incidence, mortality and stage at diagnosis.medRxiv : the preprint server for health sciences · 2026Article
- Real-world effectiveness of CDK4/6 inhibitors in older patients with HR+/HER2- advanced breast cancer: a sub-analysis of the multicenter, PALMARES-2 study.Breast (Edinburgh, Scotland) · 2026Observational
- Disparities in blood cancer survival in the UK 2009-2019: national cohort studies.BJC reports · 2026Article
- Global and regional cancer burden attributable to modifiable risk factors to inform prevention.Nature medicine · 2026Article
- The National Health Service-Galleri multicancer screening trial: explanation and justification of unique and important design issues.Journal of the National Cancer Institute · 2026Article
- Article
- European Code Against Cancer, 5th edition - occupational exposures and cancer.Molecular oncology · 2026Review
- Article
- Obstructive sleep apnea and lung cancer: molecular underpinnings and clinical translational prospects.Frontiers in cell and developmental biology · 2026Review
- Changes in life expectancy due to trends in cancer mortality rates, Spain 1980 - 2024.Frontiers in oncology · 2026Article
Corrections and comments
- Commented on by
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo examine and interpret trends in UK cancer incidence and mortality for all cancers combined and for the most common cancer sites in adults aged 35-69 years.
designRetrospective secondary data analysis. DATA SOURCES: Cancer registration data, cancer mortality and national population data from the Office for National Statistics, Public Health Wales, Public Health Scotland, Northern Ireland Cancer Registry, NHS England, and the General Register Office for Northern Ireland.
setting23 cancer sites were included in the analysis in the UK.
participantsMen and women aged 35-69 years diagnosed with or who died from cancer between 1993 to 2018.
main outcome measuresChange in cancer incidence and mortality age standardised rates over time.
resultsThe number of cancer cases in this age range rose by 57% for men (from 55 014 cases registered in 1993 to 86 297 in 2018) and by 48% for women (60 187 to 88 970) with age standardised rates showing average annual increases of 0.8% in both sexes. The increase in incidence was predominantly driven by increases in prostate (male) and breast (female) cancers. Without these two sites, all cancer trends in age standardised incidence rates were relatively stable. Trends for a small number of less common cancers showed concerning increases in incidence rates, for example, in melanoma skin, liver, oral, and kidney cancers. The number of cancer deaths decreased over the 25 year period, by 20% in men (from 32 878 to 26 322) and 17% in women (28 516 to 23 719); age standardised mortality rates reduced for all cancers combined by 37% in men (-2.0% per year) and 33% in women (-1.6% per year). The largest decreases in mortality were noted for stomach, mesothelioma, and bladder cancers in men and stomach and cervical cancers and non-Hodgkin lymphoma in women. Most incidence and mortality changes were statistically significant even when the size of change was relatively small.
conclusionsCancer mortality had a substantial reduction during the past 25 years in both men and women aged 35-69 years. This decline is likely a reflection of the successes in cancer prevention (eg, smoking prevention policies and cessation programmes), earlier detection (eg, screening programmes) and improved diagnostic tests, and more effective treatment. By contrast, increased prevalence of non-smoking risk factors are the likely cause of the observed increased incidence for a small number of specific cancers. This analysis also provides a benchmark for the following decade, which will include the impact of covid-19 on cancer incidence and outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.